Page 111 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

References 109

[21] A. Nascimento, I.F. Pinto, V. Chu, M.R. Aires-Barros, J.P. Conde, A.M.J.S. Azevedo, P.
Technology, Studies on the purification of antibody fragments. 195 (2018) 388–397.
[22] C. Mazzocco, G. Fracasso, C. Germain-Genevois, N. Dugot-Senant, M. Figini, M. Co-
lombatti, F.J.S.r. Couillaud, In vivo imaging of prostate cancer using an anti-PSMA scFv
fragment as a probe 6 (2016) 23314.
[23] D. Mercatelli, M. Bortolotti, A. Bazzocchi, A. Bolognesi, L.J.B. Polito, Immunoconju-
gates for osteosarcoma therapy: preclinical experiences and future perspectives. 6 (1)
(2018) 19.
[24] N. Norton, N. Fox, C.-A. McCarl, K.S. Tenner, K. Ballman, C.L. Erskine, C.J.B.C.R.
Calfa, Generation of HER2-specific antibody immunity during trastuzumab adju-
vant therapy associates with reduced relapse in resected HER2 breast cancer 20 (1)
(2018) 52.
[25] A. Chari, A. Suvannasankha, J.W. Fay, B. Arnulf, J.L. Kaufman, J.J. Ifthikharuddin, &
R.J. B. Comenzo, R.J. B. Daratumumab plus pomalidomide and dexamethasone in re-
lapsed and/or refractory multiple myeloma. blood-2017-2005-785246, (2017).
[26] R. Baskar, K.A. Lee, R. Yeo, K.-W.J. Yeoh, Cancer and radiation therapy: current ad-
vances and future directions. 9 (3) (2012) 193.
[27] D. Eriksson, T.J.T.B. Stigbrand, Radiation-induced cell death mechanisms. 31 (4) (2010)
363–372.
[28] S. Bockel, B. Durand, & E.J. C.R. Deutsch. Combining radiation therapy and cancer im-
mune therapies: From preclinical findings to clinical applications, (2018).
[29] R.J.T.B.j.o.r. Mole, Whole body irradiation—radiobiology or medicine? 26 (305) (1953)
234–241.
[30] J. Krombach, R. Hennel, N. Brix, M. Orth, U. Schoetz, A. Ernst, S.J.O. Bierschenk,
Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger
endothelial cell activation and recruitment of myeloid cells. 8 (1) (2019) e1523097.
[31] R.R. Weichselbaum, H. Liang, L. Deng, Y.-X.J.N.r.C.o. Fu, Radiotherapy and immuno-
therapy: a beneficial liaison? 14 (6) (2017) 365.
[32] J.J.C.r.i.o.h. Bernier, Immuno-oncology: Allying forces of radio-and immuno-therapy to
enhance cancer cell killing. 108 (2016) 97–108.
[33] J.H. Sampson, R.J. Schmittling, G.E. Archer, K.L. Congdon, S.K. Nair, E.A. Reap,
I.I.J.E.J.P.o. Herndon, A pilot study of IL-2Rα blockade during lymphopenia depletes
regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
7 (2) (2012) e31046.
[34] S. Raj, M.M. Bui, G. Springett, A. Conley, S. Lavilla-Alonso, X. Zhao, & G.D. J.S. Let-
son, Long-term clinical responses of neoadjuvant dendritic cell infusions and radiation in
soft tissue sarcoma, (2015).
[35] M.Z. Dewan, C. Vanpouille-Box, N. Kawashima, S. DiNapoli, J.S. Babb, S.C. Formenti,
S.J.C.C.R. Demaria, Synergy of topical toll-like receptor 7 agonist with radiation and
low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. 18 (24) (2012)
6668–6678.
[36] C.M. Jackson, C.M. Kochel, C.J. Nirschl, N.M. Durham, J. Ruzevick, A. Alme,
T.W.J.C.C.R. Dubensky, Systemic tolerance mediated by melanoma brain tumors is re-
versible by radiotherapy and vaccination. 22 (5) (2016) 1161–1172.
[37] M.E. Rodríguez-Ruiz, I. Rodríguez, L. Mayorga, T. Labiano, B. Barbes, I. Etxeberria, P.
Berraondo, TGFβ blockade enhances radiotherapy abscopal efficacy effects in combi-
nation with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies, Mol.
Can. Therapeu. 18 (3) (2019) 621–631.